OBJECTIVE: There is continuing controversy regarding the effect of glucocorticoids on a systemic inflammatory process. Based ona model of glucocorticoid action that includes both pro- and anti-inflammatory effects, we used the human experimental endotoxemia model to test the hypothesis that a transient elevation of plasma cortisol to stress-associated levels would enhance a subsequent (delayed) systemic inflammatory response to bacterial endotoxin. DESIGN: Prospective, randomized, double-blind, placebo-controlled clinical investigation. SETTING: Academic medical center. SUBJECTS:Thirty-six healthy human volunteers. INTERVENTIONS: Participants were randomized to receive a 6-hr intravenous infusion of saline (control), an intermediate dose of cortisol (Cort80; 6.3 mg/hr/70 kg), or a high dose of cortisol (Cort160; 12.6 mg/hr/70 kg) on day 1. On day 2, participants received an intravenous injection of 2 ng/kg Escherichia coli endotoxin followed by serial measurements of plasma cytokine concentrations. MEASUREMENTS AND MAIN RESULTS:Baseline participant characteristics and cortisol and cytokine concentrations were similar in all three groups. The plasma cortisol response to endotoxemia on day 2 was similar in all three groups. The interleukin-6 response to endotoxemia was significantly increased in the Cort80 Group compared with the control Group (p = .004), whereas the interleukin-10 response was significantly suppressed (p = .034). Corresponding results for the Cort160 Group were not significantly different from control Group values. CONCLUSIONS: In this study, transient elevation of in vivo cortisol concentrations to levels that are observed during major systemic stress enhanced a subsequent, delayed in vivo inflammatory response to endotoxin. This appeared to be a dose-dependent effect that was more prominent at intermediate concentrations of cortisol than at higher concentrations of cortisol.
RCT Entities:
OBJECTIVE: There is continuing controversy regarding the effect of glucocorticoids on a systemic inflammatory process. Based ona model of glucocorticoid action that includes both pro- and anti-inflammatory effects, we used the human experimental endotoxemia model to test the hypothesis that a transient elevation of plasma cortisol to stress-associated levels would enhance a subsequent (delayed) systemic inflammatory response to bacterial endotoxin. DESIGN: Prospective, randomized, double-blind, placebo-controlled clinical investigation. SETTING: Academic medical center. SUBJECTS: Thirty-six healthy human volunteers. INTERVENTIONS:Participants were randomized to receive a 6-hr intravenous infusion of saline (control), an intermediate dose of cortisol (Cort80; 6.3 mg/hr/70 kg), or a high dose of cortisol (Cort160; 12.6 mg/hr/70 kg) on day 1. On day 2, participants received an intravenous injection of 2 ng/kg Escherichia coli endotoxin followed by serial measurements of plasma cytokine concentrations. MEASUREMENTS AND MAIN RESULTS: Baseline participant characteristics and cortisol and cytokine concentrations were similar in all three groups. The plasma cortisol response to endotoxemia on day 2 was similar in all three groups. The interleukin-6 response to endotoxemia was significantly increased in the Cort80 Group compared with the control Group (p = .004), whereas the interleukin-10 response was significantly suppressed (p = .034). Corresponding results for the Cort160 Group were not significantly different from control Group values. CONCLUSIONS: In this study, transient elevation of in vivo cortisol concentrations to levels that are observed during major systemic stress enhanced a subsequent, delayed in vivo inflammatory response to endotoxin. This appeared to be a dose-dependent effect that was more prominent at intermediate concentrations of cortisol than at higher concentrations of cortisol.
Authors: Mark P Yeager; Athos J Rassias; Mary P Fillinger; Anthony W Discipio; Kelly E Gloor; Janice A Gregory; Paul M Guyre Journal: Crit Care Med Date: 2005-07 Impact factor: 7.598
Authors: Martijn D de Kruif; Lucienne C Lemaire; Ida A Giebelen; Marieke A D van Zoelen; Jennie M Pater; Petra S van den Pangaart; Angelique P Groot; Alex F de Vos; Peter J Elliott; Joost C M Meijers; Marcel Levi; Tom van der Poll Journal: J Immunol Date: 2007-02-01 Impact factor: 5.422
Authors: D Pietzko; D Zohlnhöfer; L Graeve; D Fleischer; T Stoyan; H Schooltink; S Rose-John; P C Heinrich Journal: J Biol Chem Date: 1993-02-25 Impact factor: 5.157
Authors: Lisa C Loram; Frederick R Taylor; Keith A Strand; Matthew G Frank; Paige Sholar; Jacqueline A Harrison; Steven F Maier; Linda R Watkins Journal: Brain Behav Immun Date: 2011-04-23 Impact factor: 7.217
Authors: Kristin A Bush; Karen Krukowski; Justin L Eddy; Linda Witek Janusek; Herbert L Mathews Journal: Cell Immunol Date: 2012-03-21 Impact factor: 4.868
Authors: Mark P Yeager; Patricia A Pioli; Jane Collins; Fiona Barr; Sara Metzler; Brian D Sites; Paul M Guyre Journal: Brain Behav Immun Date: 2016-01-11 Impact factor: 7.217
Authors: Shawn F Sorrells; Carolina D Munhoz; Nathan C Manley; Sandra Yen; Robert M Sapolsky Journal: Neuroendocrinology Date: 2014-09-10 Impact factor: 4.914